Asian Pacific Journal of Cancer Prevention

  • 제17권4호
  • /
  • Pages.1909-1915
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey

  • Arvas, Macit (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, Istanbul University) ;
  • Salihoglu, Yavuz (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University) ;
  • Sal, Veysel (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, Istanbul University) ;
  • Gungor, Tayfun (Dr Zekai Tahir Burak Womens Health Research and Education Hospital) ;
  • Sozen, Hamdullah (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University) ;
  • Kahramanoglu, Ilker (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, Istanbul University) ;
  • Topuz, Samet (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University) ;
  • Demirkiran, Fuat (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, Istanbul University) ;
  • Iyibozkurt, Cem (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University) ;
  • Bese, Tugan (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, Istanbul University) ;
  • Ozgu, Burcin Salman (Dr Zekai Tahir Burak Womens Health Research and Education Hospital) ;
  • Vatansever, Dogan (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University) ;
  • Tokgozoglu, Nedim (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, Istanbul University) ;
  • Berkman, Sinan (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University) ;
  • Turan, Hasan (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, Istanbul University) ;
  • Bengisu, Ergin (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University) ;
  • Sofiyeva, Nigar (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cerrahpasa Faculty of Medicine, Istanbul University) ;
  • Demiral, Irem (Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University) ;
  • Meydanli, Mutlu (Dr Zekai Tahir Burak Womens Health Research and Education Hospital)
  • 발행 : 2016.06.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The purpose of this study was to determine the benefit of tertiary cytoreductive surgery (TC) for secondary recurrent epithelial ovarian cancer (EOC), focusing on whether optimal cytoreduction has an impact on disease-free survival, and whether certain patient characteristics could identify ideal candidates for TC. Materials and Methods: Retrospective analysis of secondary recurrent EOC patients undergoing TC at three Turkish tertiary institutions from May 1997 to July 2014 was performed. All patients had previously received primary cytoreduction followed by intravenous platinum-based chemotherapy and secondary cytoreduction for first recurrence. Clinical and pathological data were obtained from the patients' medical records. Survival analysis was caried out using the Kaplan Meier method. Actuarial curves were compared by the two tailed Logrank test with a statistical significance level of 0.05. Results: Median age of the patients was 49.6 years (range, 30-67) and thirty-eight (72%) had stage III-IV disease at initial diagnosis. Twenty six (49%) had optimal and 27 (51%) suboptimal cytoreduction during tertiary debulking surgery. Optimal initial cytoreduction, time to first recurrence, optimal secondary cytoreduction, time interval between secondary cytoreduction and secondary recurrence, size of recurrence, disease status at last follow-up were found to be significant risk factors to predict optimal TC. Optimal cytoreduction in initial and tertiary surgery and serum CA-125 level prior to TC were independent prognostic factors on univariate analysis. Conclusions: Our results and a literature review clearly showed that maximal surgical effort should be made in TC, since patients undergoing optimal TC have a better survival. Thus, patients with secondary recurrent EOC in whom optimal cytoreduction can be achieved should be actively selected.

키워드

참고문헌

  1. Al Rawahi T, Lopes AD, Bristow RE, et al (2013). Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev, 2013, 2.
  2. Arikan SK, Kasap B, Yetimalar H, et al (2014). Impact of prognostic factors on survival rates in patients with ovarian carcinoma. Asian Pac J Cancer Prev, 15, 6087-94. https://doi.org/10.7314/APJCP.2014.15.15.6087
  3. Benedet JL, Bender H, Jones 3rd H, et al (2000). FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet, 70, 209-62. https://doi.org/10.1016/S0020-7292(00)90001-8
  4. Bristow RE, Tomacruz RS, Armstrong DK, et al (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20, 1248-59. https://doi.org/10.1200/JCO.20.5.1248
  5. Chi DS, Eisenhauer EL, Lang J, et al (2006). What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol, 103, 559-64. https://doi.org/10.1016/j.ygyno.2006.03.051
  6. Eisenkop SM, Friedman RL, Spirtos NM (2000). The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 88, 144-53. https://doi.org/10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X
  7. Fotopoulou C, Richter R, Braicu IE, et al (2011). Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol, 18, 49-57. https://doi.org/10.1245/s10434-010-1245-3
  8. Fotopoulou C, Zang R, Gultekin M, et al (2013). Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol, 20, 1348-54. https://doi.org/10.1245/s10434-012-2673-z
  9. Gultekin M, Velipasaoglu M, Aksan Guldeniz, et al (2008). A Third Evaluation of Tertiary Cytoreduction. J Surgical Oncol, 98, 530-4. https://doi.org/10.1002/jso.21146
  10. Harter P, du Bois A, Hahmann M, et al ( 2006). Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol, 13, 1702-10. https://doi.org/10.1245/s10434-006-9058-0
  11. Hizli D, Boran N, Yilmaz S, et al (2012). Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol, 163, 71-5. https://doi.org/10.1016/j.ejogrb.2012.03.018
  12. Karam AK, Santillan A, Bristow RE, et al (2007). Tertiary cytoreductive surgery in recurrent ovarian cancer: Selection criteria and survival outcome. Gynecol Oncol, 104, 377-80. https://doi.org/10.1016/j.ygyno.2006.08.037
  13. Leitao MM, Kardos S, Barakat RR, et al (2004). Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol, 95, 181-8. https://doi.org/10.1016/j.ygyno.2004.07.033
  14. Maldonado G, Greenland S (1993). Simulation study of confounder-selection strategies. Am J Epidemiol, 138, 923-36. https://doi.org/10.1093/oxfordjournals.aje.a116813
  15. Sehouli J, Richter R, Braicu EI, et al (2010). Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol, 102, 656-62. https://doi.org/10.1002/jso.21652
  16. Shih KK, Chi DS, Barakat RR, et al (2010). Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol, 117, 330-5. https://doi.org/10.1016/j.ygyno.2010.01.046
  17. Tang J, Liu LD, Shu S, et al (2013). Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: Implications for tertiary cytoreductive surgery. EJSO, 39, 786-91. https://doi.org/10.1016/j.ejso.2013.02.006
  18. Zang RY, Li ZT, Tang J, et al (2004). Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer, 100, 1152-61. https://doi.org/10.1002/cncr.20106